drugset / Trial / NCT03451396

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396

Phase 4 Completed 30 enrolled Lifelong Vision Foundation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.

Timeline

Start
2016-12-12
Primary completion
2018-02-01
Completion
2018-03-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lifitegrast Unknown 5 % Topical

Indications